Oral semaglutide as effective as injectable

obesity: overweight person holds bulge over hip
Ozempic/Wegovy sponsor trumpets results of Phase III clinical trial as its halts US ads A trial of an oral version of Novo Nordisk’s obesity and diabetes medication semaglutide, the active ingredient in high profile potential blockbuster drugs Ozempic and Wegovy, appears to deliver similar results to the incredibly popular injectable versions of the  treatments. These

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous ‘We don’t realise how valuable pharmacists are’
Next Research Roundup